Taishi Nada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Taishi Nada has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Kentaro Nishi
Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan
2 shared publications - Koichi Kamei
Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan
2 shared publications Masao Ogura
Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan
2 shared publications- Shuichi Ito
Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Japan
2 shared publications Aya Inaba
Department of Pediatrics, Yokohama City University Medical Center, Yokohama, Japan
1 shared publication- Aya Inaba
Department of Pediatrics, Yokohama City University Medical Center, Kanagawa, Japan
1 shared publication
Latest Publications
- 12 June 2026
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (12) , 4423-4432
Discontinuation of mycophenolate mofetil as maintenance therapy after rituximab treatment in childhood-onset complicated frequently relapsing or steroid-dependent nephrotic syndrome
Mycophenolate mofetil (MMF) as maintenance therapy after rituximab treatment is effective in preventing relapses in children with complicated frequently relapsing or steroid-dependent nephrotic syndrome. However, once sustained remission has been achieved by MMF, the outcomes and risk of relapse after discontinuing MMF remain unclear. We conducted a two-center, retrospective study of patients with childhood-onset frequently relapsing or steroid-dependent nephrotic syndrome who discontinued MMF because of sustained remission for ≥ 2 years on maintenance MMF after rituximab treatment. Relapse, additional treatment, and risk factors for relapses after MMF discontinuation were analyzed. Sixty patients were enrolled. After tapering or discontinuation of MMF, 35 (58%) patients relapsed, and the median time from tapering to relapse was 276 days. The 50% relapse-free survival was 1.5 years using the Kaplan-Meier method. After relapses, 30 (86%) patients required reinitiation of immunosuppressants or additional rituximab treatment. The history of initial steroid-resistant nephrotic syndrome, relapses < 10 times before the first rituximab treatment with immunosuppressants, and a longer period between the last B-cell recovery and tapering MMF were significantly associated with a lower risk of relapse in a multivariate analysis using the Cox proportional hazards model (all p < 0.05). Discontinuation of MMF may be considered in selected patients with sustained remission after rituximab treatment, particularly those with identified low-risk factors for relapse. The timing of discontinuation should be individualized according to these factors and patient-specific considerations because resumption of immunosuppressants or additional rituximab treatment is frequently required after relapse following MMF discontinuation.
- 12 June 2026
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (12) , 4423-4432
Discontinuation of mycophenolate mofetil as maintenance therapy after rituximab treatment in childhood-onset complicated frequently relapsing or steroid-dependent nephrotic syndrome
Mycophenolate mofetil (MMF) as maintenance therapy after rituximab treatment is effective in preventing relapses in children with complicated frequently relapsing or steroid-dependent nephrotic syndrome. However, once sustained remission has been achieved by MMF, the outcomes and risk of relapse after discontinuing MMF remain unclear. We conducted a two-center, retrospective study of patients with childhood-onset frequently relapsing or steroid-dependent nephrotic syndrome who discontinued MMF because of sustained remission for ≥ 2 years on maintenance MMF after rituximab treatment. Relapse, additional treatment, and risk factors for relapses after MMF discontinuation were analyzed. Sixty patients were enrolled. After tapering or discontinuation of MMF, 35 (58%) patients relapsed, and the median time from tapering to relapse was 276 days. The 50% relapse-free survival was 1.5 years using the Kaplan-Meier method. After relapses, 30 (86%) patients required reinitiation of immunosuppressants or additional rituximab treatment. The history of initial steroid-resistant nephrotic syndrome, relapses < 10 times before the first rituximab treatment with immunosuppressants, and a longer period between the last B-cell recovery and tapering MMF were significantly associated with a lower risk of relapse in a multivariate analysis using the Cox proportional hazards model (all p < 0.05). Discontinuation of MMF may be considered in selected patients with sustained remission after rituximab treatment, particularly those with identified low-risk factors for relapse. The timing of discontinuation should be individualized according to these factors and patient-specific considerations because resumption of immunosuppressants or additional rituximab treatment is frequently required after relapse following MMF discontinuation.
- 3 September 2025
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 29 (12) , 1829-1839
Long-term outcome of mycophenolate mofetil after a single dose of rituximab in childhood-onset refractory idiopathic nephrotic syndrome
Background Maintenance therapy using immunosuppressive agents after rituximab can be effective for sustaining remission in childhood-onset refractory frequently relapsing nephrotic syndrome/steroid-dependent nephrotic syndrome (FRNS/SDNS). We evaluated the long-term outcome of mycophenolate mofetil (MMF) after rituximab. Methods We conducted a multicenter, retrospective cohort study of patients with childhood-onset refractory FRNS/SDNS who received MMF as maintenance therapy after a single dose of rituximab and were followed up ≥ 2 years at three pediatric renal centers. Relapses, additional treatment, risk factors for relapse, and adverse events were analyzed. Results We enrolled 106 patients, and the median follow-up was 7.2 years. Forty-seven (44%) patients had no relapse under MMF, and the 50% relapse-free survival was 3.2 years during MMF administration. Sixty-one (58%) patients required additional rituximab during the observation period. The mean annual number of relapses before the first rituximab treatment versus 1 year after rituximab initiation was 3.7 (standard deviation: 1.3) versus 0.4 (standard deviation: 0.8) times (p < 0.0001). Sixty-six of 74 (89%) patients could discontinue calcineurin inhibitors within 1 year after rituximab. MMF < 1000 mg/m2 was an independent significant risk factor for the first relapse (p = 0.03). No fatal adverse events and 23 episodes of infection requiring hospitalization were observed during the study period. Conclusions MMF after a single dose of rituximab is safe and effective in achieving a long relapse-free period and discontinuing a calcineurin inhibitor in patients with refractory FRNS/SDNS.
- 3 September 2025
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 29 (12) , 1829-1839
Long-term outcome of mycophenolate mofetil after a single dose of rituximab in childhood-onset refractory idiopathic nephrotic syndrome
Background Maintenance therapy using immunosuppressive agents after rituximab can be effective for sustaining remission in childhood-onset refractory frequently relapsing nephrotic syndrome/steroid-dependent nephrotic syndrome (FRNS/SDNS). We evaluated the long-term outcome of mycophenolate mofetil (MMF) after rituximab. Methods We conducted a multicenter, retrospective cohort study of patients with childhood-onset refractory FRNS/SDNS who received MMF as maintenance therapy after a single dose of rituximab and were followed up ≥ 2 years at three pediatric renal centers. Relapses, additional treatment, risk factors for relapse, and adverse events were analyzed. Results We enrolled 106 patients, and the median follow-up was 7.2 years. Forty-seven (44%) patients had no relapse under MMF, and the 50% relapse-free survival was 3.2 years during MMF administration. Sixty-one (58%) patients required additional rituximab during the observation period. The mean annual number of relapses before the first rituximab treatment versus 1 year after rituximab initiation was 3.7 (standard deviation: 1.3) versus 0.4 (standard deviation: 0.8) times (p < 0.0001). Sixty-six of 74 (89%) patients could discontinue calcineurin inhibitors within 1 year after rituximab. MMF < 1000 mg/m2 was an independent significant risk factor for the first relapse (p = 0.03). No fatal adverse events and 23 episodes of infection requiring hospitalization were observed during the study period. Conclusions MMF after a single dose of rituximab is safe and effective in achieving a long relapse-free period and discontinuing a calcineurin inhibitor in patients with refractory FRNS/SDNS.